Metraipolis › archive › dc_fc2393eef420
Pharmacokinetics, safety, and dose optimization of GST-HG171 in renal impairment: insights from physiologically based pharmacokinetic modeling — Europe PMC PMID:42455066
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42455066
- DOI
- 10.1128/aac.01541-25
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T06:57:22.577Z
- SHA-256 of the archived text
55a42199b61f6fcc3cf8fb84c94f12f06098a80bb9f12a05534b9bb7bed891be- Stable URL of this page
https://metraipolis.com/documento/dc_fc2393eef420
How to cite
Pharmacokinetics, safety, and dose optimization of GST-HG171 in renal impairment: insights from physiologically based pharmacokinetic modeling — Europe PMC PMID:42455066 — Europe PMC (en), https://europepmc.org/article/MED/42455066 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fc2393eef420 (Metraipolis archive dc_fc2393eef420, sha256 55a42199b61f6fcc3cf8fb84c94f12f06098a80bb9f12a05534b9bb7bed891be)
BibTeX
@misc{dcfc2393eef420,
title = {Pharmacokinetics, safety, and dose optimization of GST-HG171 in renal impairment: insights from physiologically based pharmacokinetic modeling — Europe PMC PMID:42455066},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42455066},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fc2393eef420; sha256 55a42199b61f6fcc3cf8fb84c94f12f06098a80bb9f12a05534b9bb7bed891be},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42455066. Agents can read the archived copy with the MCP tool read_document.